Drug intelligence / Profile preview

Fuzheng Tongluo granules

Development stage: Unknown
Lead developer: Shuguang Hospital
Administration: Oral

Overview

Fuzheng Tongluo granules is a Traditional Chinese Medicine (TCM) herbal formulation developed by Shuguang Hospital affiliated to Shanghai University of Traditional Chinese Medicine. It is specifically designed for the treatment of idiopathic pulmonary fibrosis (IPF), particularly in patients presenting with the kidney-deficiency and collateral-stasis pattern according to TCM diagnostic criteria. The formulation is intended to be used as an adjunctive therapy to standard-of-care treatments such as nintedanib. It aims to improve clinical outcomes, lung function, and quality of life by addressing the underlying TCM pathogenesis of fibrosis through its multi-component herbal constituents that traditionally tonify the kidney and resolve blood stasis.

Other names: Fuzheng Tongluo Keli

Beyond the preview

Go deeper on Fuzheng Tongluo granules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fuzheng Tongluo granules.

Explore the full profile